SCL Science Inc. (KOSDAQ:246960)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,090.00
-55.00 (-2.56%)
At close: Apr 28, 2026
2.58%
Market Cap 68.37B
Revenue (ttm) 22.01B
Net Income (ttm) -3.93B
Shares Out 34.02M
EPS (ttm) -120.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 143,561
Average Volume 129,131
Open 2,145.00
Previous Close 2,145.00
Day's Range 2,035.00 - 2,145.00
52-Week Range 1,770.00 - 5,110.00
Beta 0.55
RSI 39.46
Earnings Date Apr 3, 2026

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 246960
Full Company Profile

Financial Performance

In 2025, SCL Science's revenue was 22.01 billion, an increase of 364.64% compared to the previous year's 4.74 billion. Losses were -3.93 billion, 5.47% more than in 2024.

Financial Statements

News

There is no news available yet.